Lipid-lowering drug therapy for reducing cardiovascular risk in diabetes. A clinical view of the Cardiovascular Disease Working Group of the Spanish Diabetes Society Juan Pedro-Botet; Francisco Arrieta; Manuel Botana; José A. Gimeno-Orna; José I. Martínez-Montoro; Emilio Ortega-Martínez de Victoria; Josep Ribalta; Víctor Sánchez-Margalet; Antonio Pérez-Pérez;

Cost-effectiveness evaluation of the use of PCSK9 inhibitors Fernando Civeira; Juan Pedro-Botet;

Impact of the presence and type of cardiovascular disease on the risk of mortality in type 2 diabetic patients: The DIABET-IC trial José Antonio Gimeno Orna; Ana Belén Mañas Martínez; Luis Rodríguez Padial; Manuel Anguita Sánchez; Vivencio Barrios; Javier Muñiz García; Antonio Pérez Pérez;